Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

Slides:

Advertisements

Similar presentations

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.

Advertisements

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.

COG Stephen Hunger, MD William Carroll, MD Gregory Reaman, MD Paul Bowman, MD Mini Devidas, PhD University of New Mexico Cheryl Willman,

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia by Jose Claudio C. Rocha, Cheng Cheng, Wei Liu, Shinji Kishi, Soma Das, Edwin.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using “MRD lite” panel Brig Tathagata Chatterjee,

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

TCR-MHC-peptide(s): in vivo veritas

Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia by Chun-Lin Chen, Qing Liu, Ching-Hon Pui,

Building better therapy for children with acute lymphoblastic leukemia

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Juvenile Myelomonocytic Leukemia

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia by Jun J. Yang, Cheng.

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Stage C or not stage C…? by Claire Dearden Blood

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,

Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic.

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Minimal Residual Disease and Hematologic Malignancies

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

by Moshe Yeshurun, Daniel Weisdorf, Jacob M. Rowe, Martin S

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Overall survival among children with acute lymphoblastic leukemia who were enrolled in Children's Cancer Group and Children's Oncology Group clinical trials,

EN1 expression in breast cancer and clinical outcome.

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Patient stratification using survival risk prediction and BCLC staging

Two major molecular subgroups within PTCL-NOS with biological and overall survival differences. Two major molecular subgroups within PTCL-NOS with biological.

How I treat T-cell acute lymphoblastic leukemia in adults

Cold agglutinin disease

Presentation transcript:

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia by Huining Kang, I.-Ming Chen, Carla S. Wilson, Edward J. Bedrick, Richard C. Harvey, Susan R. Atlas, Meenakshi Devidas, Charles G. Mullighan, Xuefei Wang, Maurice Murphy, Kerem Ar, Walker Wharton, Michael J. Borowitz, W. Paul Bowman, Deepa Bhojwani, William L. Carroll, Bruce M. Camitta, Gregory H. Reaman, Malcolm A. Smith, James R. Downing, Stephen P. Hunger, and Cheryl L. Willman Blood Volume 115(7): February 18, 2010 ©2010 by American Society of Hematology

Performance of the 42-probe-set (38-gene) gene expression classifier for prediction of RFS. (A- B) Kaplan-Meier survival estimates of RFS in the full cohort of 207 patients (A) and in the low- versus high-risk groups distinguished with the gene expression cl... Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology

Kaplan-Meier estimates of RFS based on the gene expression classifier for RFS and end- induction (day 29) MRD. (A) Day 29 flow cytometric measures of MRD separated patients into 2 groups with significantly different RFS. (B-C) After dividing patients by thei... Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology

Kaplan-Meier estimates of RFS based on the gene expression classifier for RFS modeled on high-risk ALL cases lacking known recurring cytogenetic abnormalities and end-induction (day 29) MRD. (A) The second gene expression classifier modeled only on those hi... Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology

Gene expression classifier for prediction of end-induction (day 29) flow MRD in pretreatment samples combined with the gene expression classifier for RFS. (A) A ROC shows the high accuracy of the 23-probe-set MRD classifier (LOOCV error rate of 24.61%; sens... Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology

Kaplan-Meier estimates of RFS using the combined gene expression classifiers for RFS and MRD in an independent cohort of 84 children with high-risk ALL. (A) The gene expression classifier for RFS separates children into low- and high-risk groups in an indep... Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology

Kaplan-Meier estimates of RFS using the combined gene expression classifier for RFS and flow cytometric measures of MRD in the presence of kinase signatures, JAK mutations, and IKAROS/IKZF1 deletions. Huining Kang et al. Blood 2010;115: ©2010 by American Society of Hematology